Use of crizotinib for refractory ALK-positive lymphomas-Reference-Cited by-同舟云学术

Use of crizotinib for refractory ALK-positive lymphomas

Published:2017-07-15 Issue:7 Volume:89 Page:51-56
ISSN:2309-5342
Container-title:Terapevticheskii arkhiv
language:
Short-container-title:Terapevticheskii arkhiv

Author:

Shelikhova L N,Fominykh V V,Abramov D S,Myakova N V,Maschan M A,Maschan A A

Abstract

Aim. To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects and methods. The paper describes the experience with crizotinib used in 8 patients with refractory ALK-ALCL before and after allogeneic hematopoietic stem cell transplantation (HSCT). Results. All the 8 (100%) patients treated with crizotinib were recorded to have complete responses, including complete metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography. Conclusion. Low and manageable toxicity of crizotinib and complete PET-negative responses in patients with resistant ALK lymphomas favor the need to test the drug as first-line therapy, by possibly decreasing the intensification of chemotherapy.

Publisher

Consilium Medicum

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice

Link

https://ter-arkhiv.ru/0040-3660/article/viewFile/32269/pdf

Reference25 articles.

1. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: Findings from the UK Children’s Cancer Study Group. J Clin Pathol. 1997;50:128-134. https://doi.org/10.1136/jcp.50.2.128

2. Elias Campo, Steven H. Swerdlow, Nancy L. Harris, Stefano Pileri, Harald Stein and Elaine S. Jaffe Anaplastic large cell lymphoma, ALK-positive. WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008), p. 312-316. https://doi.org/10.1002/9781118853771.ch51

3. Lamant L, de Reyni es A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugi eres L, Gaulard P, Espinos E, Delsol G. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109:2156-2164. https://doi.org/10.1182/blood-2006-06-028969

4. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281-1284. https://doi.org/10.1126/science.8122112

5. Chiarle R, Voena C, Ambrogio Ch, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11-23. https://doi.org/10.1038/nrc2291

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traditional and emerging therapies for anaplastic large cell lymphoma (Review);International Journal of Oncology;2021-06-14

2. High-dose polychemotherapy with autologous hematopoietic stem cell transplantation in children with non-Hodgkin lymphomas;Pediatric Hematology/Oncology and Immunopathology;2021-05-22

3. The use of checkpoint inhibitors in children with non-Hodgkin lymphomas;Pediatric Hematology/Oncology and Immunopathology;2020-07-02